Koc University Hospital Researchers Release New Study Findings on Necrotizing Fasciitis (Necrotizing Fasciitis as Complication of Combined Use of Bevacizumab with Chemotherapy).

Keywords: Antineoplastic Monoclonal Antibodies; Antineoplastics; Bevacizumab Therapy; Chemotherapy; Drugs and Therapies; Fasciitis; Health and Medicine; Immunologic Agents; Monoclonal Antibodies; Musculoskeletal Diseases and Conditions; Necrotizing Fasciitis; Pharmaceuticals; Risk and Prevention; Tyrosine Kinase Inhibitors; VEGF - VEGFR Inhibitors; VEGFR Inhibitors EN Antineoplastic Monoclonal Antibodies Antineoplastics Bevacizumab Therapy Chemotherapy Drugs and Therapies Fasciitis Health and Medicine Immunologic Agents Monoclonal Antibodies Musculoskeletal Diseases and Conditions Necrotizing Fasciitis Pharmaceuticals Risk and Prevention Tyrosine Kinase Inhibitors VEGF - VEGFR Inhibitors VEGFR Inhibitors 437 437 1 03/23/23 20230320 NES 230320 2023 MAR 21 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on necrotizing fasciitis have been published. According to news originating from Istanbul, Turkey, by NewsRx editors, the research stated, "Necrotizing fasciitis (NF) is an uncommon, severe, life-threatening soft tissue infection involving the subcutaneous tissue.". [Extracted from the article]

Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)